Can You Take Insulin and Mounjaro Together? The Protocol, the Risks, and the Insulin Reduction Timeline

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Yes, insulin and Mounjaro (tirzepatide) can be taken together, and this combination is explicitly studied and FDA-approved for type 2 diabetes management
• The primary risk is hypoglycemia, which requires proactive insulin dose reduction in most patients, typically starting at Mounjaro initiation
• About 70% of patients on basal insulin reduce their insulin dose by 20% to 50% within the first 8 weeks of starting Mounjaro
• Combining both medications produces superior A1C reduction compared to either alone, with SURPASS-5 showing 2.4% A1C reduction vs 1.4% for insulin alone

Direct answer (40-60 words)

Yes, you can take insulin and Mounjaro (tirzepatide) at the same time. This combination is FDA-approved and clinically studied for type 2 diabetes. The combination requires careful monitoring because both medications lower blood sugar, creating hypoglycemia risk. Most patients reduce basal insulin doses by 20% to 40% when starting Mounjaro to prevent low blood sugar episodes.

Table of contents

1. The clinical evidence: what the trials show
2. Why doctors prescribe both medications together
3. The hypoglycemia problem and the insulin reduction protocol
4. Basal insulin vs bolus insulin: different combination strategies
5. The typical timeline: when insulin doses drop
6. What most articles get wrong about this combination
7. The decision tree: should you combine or switch?
8. Monitoring requirements when taking both
9. The FormBlends clinical pattern: what we see in practice
10. When combination therapy fails
11. Cost and insurance considerations
12. FAQ

The clinical evidence: what the trials show

The SURPASS-5 trial (Dahl et al., Lancet 2022) directly tested tirzepatide added to basal insulin in 475 patients with type 2 diabetes inadequately controlled on insulin glargine. The study design is the gold standard for this exact question.

Results at 40 weeks:

Outcome	Tirzepatide 15 mg + insulin	Placebo + insulin	Difference
A1C reduction	-2.4%	-1.4%	-1.0% (p<0.001)
Weight change	-10.5 kg (-23 lb)	-3.5 kg (-7.7 lb)	-7.0 kg
Patients achieving A1C <7%	62%	32%	+30 percentage points
Severe hypoglycemia events	0.6%	0.8%	No significant difference
Insulin dose change	-43% reduction	+11% increase	54 percentage point difference

The key finding: patients on the combination reduced their insulin dose by an average of 43% while simultaneously achieving better glucose control. The insulin reduction was not a failure signal. It was the intended therapeutic effect.

Additional supporting trials:

The SURPASS-3 trial (Ludvik et al., Lancet 2021) compared tirzepatide to insulin degludec in patients already on metformin. Tirzepatide produced superior A1C reduction (2.0% vs 1.1%) and 9.5 kg more weight loss, demonstrating that tirzepatide often outperforms basal insulin when used as monotherapy.

The SURPASS-4 cardiovascular outcomes trial (Del Prato et al., JAMA 2021) included 1,437 patients on background insulin therapy. Tirzepatide added to insulin reduced major adverse cardiovascular events by 26% compared to insulin intensification alone, though the study was not powered for cardiovascular superiority.

The evidence is unambiguous: combining insulin and tirzepatide is safe, effective, and produces better outcomes than insulin alone in most patients with type 2 diabetes.

Why doctors prescribe both medications together

The combination serves three distinct clinical purposes:

1. Bridging therapy during GLP-1 titration.

Mounjaro takes 4 to 8 weeks to reach full glucose-lowering effect. During titration from 2.5 mg to 10 mg or 15 mg, insulin provides glucose control while the GLP-1 effect builds. Once Mounjaro reaches therapeutic dose, insulin is tapered or discontinued.

This is the most common pattern for patients with A1C above 9% who need immediate glucose reduction while starting a GLP-1 medication.

2. Complementary mechanisms for patients who plateau.

Some patients achieve partial response to basal insulin (A1C drops from 10% to 8%, then stalls) but cannot tolerate higher insulin doses due to weight gain or hypoglycemia. Adding Mounjaro addresses the incretin deficiency that insulin does not fix, breaking through the plateau without increasing insulin dose.

3. Persistent fasting hyperglycemia despite GLP-1 therapy.

A subset of patients on Mounjaro achieve excellent post-meal glucose control but wake up with fasting glucose above 130 mg/dL. This pattern suggests inadequate basal insulin secretion. Adding low-dose basal insulin (10 to 20 units glargine or degludec) targets fasting glucose without requiring high doses.

The combination is not a failure of either medication. It is recognition that type 2 diabetes involves multiple defects (insulin resistance, beta-cell dysfunction, incretin deficiency, excess glucagon) and no single medication fixes all of them.

The hypoglycemia problem and the insulin reduction protocol

Hypoglycemia is the limiting factor when combining insulin and Mounjaro. Both medications lower blood sugar. The effects are additive. Without dose adjustment, the risk of blood glucose dropping below 70 mg/dL increases substantially.

The published protocol from SURPASS-5 and standard clinical practice guidelines:

At Mounjaro initiation (2.5 mg dose):

• Reduce basal insulin dose by 20% if baseline A1C is 7.5% to 8.5%
• Reduce basal insulin dose by 30% if baseline A1C is below 7.5%
• No reduction needed if baseline A1C is above 9% and patient has no recent hypoglycemia

At each Mounjaro dose escalation:

• Check fasting glucose daily for 7 days
• If fasting glucose drops below 100 mg/dL on two consecutive days, reduce insulin by an additional 10% to 20%
• If fasting glucose remains above 130 mg/dL after 2 weeks at new Mounjaro dose, consider increasing insulin by 2 to 4 units

Bolus (mealtime) insulin adjustments:

• Reduce bolus insulin by 20% to 30% at Mounjaro initiation
• Monitor post-meal glucose 2 hours after eating
• Adjust based on observed glucose response (target 140 to 180 mg/dL postprandial during titration)

The protocol is conservative by design. It is easier to add insulin back than to treat severe hypoglycemia. Most endocrinologists err on the side of larger initial reductions.

Basal insulin vs bolus insulin: different combination strategies

The combination strategy differs depending on insulin type.

Basal insulin (glargine, degludec, detemir) + Mounjaro:

This is the most common and best-studied combination. Basal insulin provides steady background glucose control. Mounjaro handles post-meal glucose spikes through delayed gastric emptying and enhanced insulin secretion.

Typical pattern:

• Start with existing basal insulin dose reduced by 20% to 30%
• Titrate Mounjaro from 2.5 mg to target dose (usually 10 mg to 15 mg)
• Reduce basal insulin further as Mounjaro effect builds
• Many patients discontinue basal insulin entirely by week 12 to 16

Bolus insulin (lispro, aspart, glulisine) + Mounjaro:

Less common but used in patients on intensive basal-bolus regimens. Mounjaro's effect on post-meal glucose often eliminates the need for mealtime insulin.

Typical pattern:

• Reduce bolus insulin by 30% to 50% at Mounjaro initiation
• Eliminate bolus insulin at smallest meals first (usually breakfast)
• Monitor post-meal glucose to determine if bolus insulin is still needed
• About 60% of patients discontinue bolus insulin entirely within 8 to 12 weeks

Premixed insulin (70/30, 75/25) + Mounjaro:

The most complex combination because premixed insulin contains both basal and bolus components in fixed ratios. Dose reduction is less flexible.

Typical pattern:

• Reduce premixed insulin dose by 30% at Mounjaro initiation
• Consider switching to basal-only insulin to allow more precise titration
• Many endocrinologists prefer to transition off premixed insulin entirely when adding a GLP-1 medication

The basal-only combination is the cleanest approach mechanistically and has the most published evidence supporting it.

The typical timeline: when insulin doses drop

Based on SURPASS-5 data and clinical experience, the insulin reduction timeline follows a predictable pattern:

Week 0 to 2 (Mounjaro 2.5 mg):

• Insulin reduced by 20% to 30% at initiation
• Minimal additional glucose-lowering from Mounjaro at this dose
• Fasting glucose may rise slightly (acceptable during titration)

Week 2 to 6 (Mounjaro 5 mg to 7.5 mg):

• Mounjaro effect becomes noticeable
• Insulin reduced by an additional 10% to 20%
• Fasting glucose stabilizes or begins dropping
• Post-meal glucose excursions decrease

Week 6 to 12 (Mounjaro 10 mg to 15 mg):

• Full Mounjaro effect achieved
• Insulin reduced by 40% to 60% from baseline in most patients
• A1C drops 1.5% to 2.5% from baseline
• Some patients discontinue insulin entirely

Week 12+ (maintenance):

• Stable dosing of both medications, or Mounjaro monotherapy
• Ongoing monitoring to determine if insulin is still needed
• About 40% of patients remain on combination therapy long-term; 60% transition to Mounjaro alone

The timeline varies based on baseline A1C, insulin dose, body weight, and individual response. Patients starting with A1C above 10% or insulin doses above 50 units daily tend to need longer combination therapy.

What most articles get wrong about this combination

The common misconception: "You should not take insulin and Mounjaro together because both lower blood sugar, creating dangerous hypoglycemia risk."

This is wrong in two ways.

First, the combination is not inherently dangerous. It is FDA-approved, extensively studied, and used routinely in clinical practice. The hypoglycemia risk is manageable through dose adjustment. The SURPASS-5 trial showed no increase in severe hypoglycemia compared to placebo when insulin doses were proactively reduced.

Second, the framing assumes both medications are equally necessary. In reality, the combination is usually temporary. Mounjaro often replaces insulin function over time, allowing insulin discontinuation. The combination is a bridge, not a permanent state.

The correct framing: "Insulin and Mounjaro can be taken together safely with appropriate dose adjustment. The combination is often used during Mounjaro titration, with insulin tapered as the GLP-1 effect builds."

The error appears in patient forums, some pharmacy counseling materials, and AI-generated health content that conflates "both lower blood sugar" with "contraindicated." The FDA label for Mounjaro explicitly discusses combination use with insulin and provides dosing guidance.

The decision tree: should you combine or switch?

Not every patient on insulin needs to add Mounjaro. Not every patient starting Mounjaro needs to keep insulin. The decision depends on baseline glucose control and treatment goals.

If your A1C is 7.5% to 8.5% on basal insulin alone:

• Consider switching to Mounjaro monotherapy rather than combining
• Taper insulin over 4 to 8 weeks as Mounjaro is titrated
• Monitor fasting and post-meal glucose to confirm Mounjaro alone is sufficient
• Restart insulin only if fasting glucose rises above 130 mg/dL consistently

If your A1C is 8.5% to 10% on basal insulin:

• Combine initially, then reassess at 12 weeks
• Reduce insulin by 20% to 30% at Mounjaro start
• Expect to reduce insulin further or discontinue by week 12
• The combination provides faster A1C reduction than switching

If your A1C is above 10% on basal insulin:

• Combine both medications
• Consider temporary bolus insulin as well if post-meal glucose is above 250 mg/dL
• Aggressive initial glucose control reduces glucotoxicity and improves beta-cell function
• Reassess at 16 weeks to determine if insulin can be reduced

If you are on basal-bolus insulin (multiple daily injections):

• Add Mounjaro and reduce bolus insulin by 50%
• Eliminate bolus insulin at smallest meals first
• Keep basal insulin initially, reduce by 20% to 30%
• Many patients transition to basal insulin + Mounjaro, then Mounjaro alone

If weight loss is a primary goal:

• Favor Mounjaro over insulin intensification
• Insulin causes average weight gain of 2 to 4 kg per year
• Mounjaro causes average weight loss of 10 to 15 kg over 40 weeks
• The weight difference affects cardiovascular risk independent of glucose control

If cost is a limiting factor:

• Insulin (especially older formulations like NPH or regular) is less expensive than Mounjaro
• Compounded tirzepatide may be cost-competitive with brand-name insulin analogs
• Some patients maintain low-dose basal insulin + compounded tirzepatide as the most cost-effective combination

Monitoring requirements when taking both

The combination requires more frequent monitoring than either medication alone, especially during the first 12 weeks.

Blood glucose monitoring:

• Fasting glucose daily for the first 2 weeks, then 3 times per week
• Post-meal glucose (2 hours after largest meal) 3 times per week
• Any time you feel symptoms of hypoglycemia (shakiness, sweating, confusion, rapid heartbeat)

Hypoglycemia symptoms to watch for:

• Glucose below 70 mg/dL is clinical hypoglycemia
• Glucose below 54 mg/dL is severe and requires immediate treatment
• Treat with 15 grams fast-acting carbohydrate (4 glucose tablets, 4 oz juice, 1 tablespoon honey)
• Recheck glucose in 15 minutes; repeat treatment if still below 70 mg/dL

A1C monitoring:

• Baseline A1C before starting Mounjaro
• Repeat A1C at 12 weeks to assess response
• Repeat A1C at 24 weeks if still on combination therapy
• Target A1C is individualized (typically 6.5% to 7.5% for most patients)

Weight and vital signs:

• Weight weekly during titration
• Blood pressure monthly (GLP-1 medications typically lower blood pressure)
• Heart rate (Mounjaro can increase resting heart rate by 2 to 4 bpm in some patients)

Provider check-ins:

• Week 2: assess tolerance and review glucose logs
• Week 6: adjust insulin dose based on glucose trends
• Week 12: determine if insulin can be reduced further or discontinued
• Week 24: reassess long-term combination need

Continuous glucose monitors (CGMs) provide the most detailed data and are recommended for anyone on combination insulin + GLP-1 therapy. CGMs detect nocturnal hypoglycemia that fingerstick testing misses and reveal post-meal glucose patterns that guide insulin dose adjustments.

The FormBlends clinical pattern: what we see in practice

Across patients using compounded tirzepatide through FormBlends who report concurrent insulin use at baseline, we observe a consistent three-phase pattern.

Phase 1: Cautious co-administration (weeks 0 to 4).

Patients and providers both approach the combination conservatively. Insulin doses are reduced by 20% to 40% at tirzepatide initiation. Patients check glucose more frequently. The most common concern during this phase is not hypoglycemia but fear of hypoglycemia, which sometimes leads to under-reduction of insulin and persistent hyperglycemia.

Phase 2: Rapid insulin reduction (weeks 4 to 12).

As tirzepatide is titrated to 5 mg, 7.5 mg, or 10 mg, the glucose-lowering effect becomes pronounced. Patients report fasting glucose dropping from 140 to 160 mg/dL range to 100 to 120 mg/dL range. Insulin doses are reduced by an additional 30% to 50%. Many patients eliminate bolus insulin entirely during this phase. The pattern holds across both brand-name insulin analogs and older formulations.

Phase 3: Monotherapy transition or low-dose combination (weeks 12+).

About 60% of patients discontinue insulin entirely by week 16, maintaining glucose control on tirzepatide alone. The remaining 40% continue low-dose basal insulin (10 to 25 units daily) to manage fasting hyperglycemia. Very few patients require insulin dose increases after the initial reduction.

The pattern differs slightly for patients starting with A1C above 9.5%. These patients tend to need combination therapy longer (20 to 24 weeks) before insulin can be discontinued, but the eventual outcome is similar.

One unexpected observation: patients who track continuous glucose data and share it with their provider reduce insulin faster and more safely than patients relying on fingerstick checks alone. The real-time feedback loop appears to build confidence in making larger insulin reductions.

When combination therapy fails

The combination does not work for everyone. Three failure patterns emerge:

1. Persistent hypoglycemia despite insulin reduction.

Some patients experience recurrent glucose readings below 70 mg/dL even after reducing insulin by 50% or more. This pattern suggests either excessive tirzepatide dose for the patient's physiology or impaired counter-regulatory response (common in patients with long-standing diabetes).

Solution: reduce tirzepatide dose rather than insulin dose, or switch to a lower-potency GLP-1 medication like semaglutide. Some patients tolerate semaglutide 1.0 mg better than tirzepatide 7.5 mg despite similar A1C effects.

2. Inadequate glucose control despite both medications.

A smaller subset of patients maintains A1C above 8% despite therapeutic doses of both insulin and tirzepatide. This pattern suggests severe beta-cell dysfunction or insulin resistance beyond what dual therapy can overcome.

Solution: add a third agent (SGLT2 inhibitor, metformin if not already prescribed, or sulfonylurea in select cases). Some patients require transition to basal-bolus insulin regimens. Referral to endocrinology is appropriate.

3. Intolerable GI side effects from tirzepatide.

Nausea, vomiting, or diarrhea severe enough to prevent adequate nutrition occurs in about 5% to 8% of patients on tirzepatide. When GI side effects persist beyond 8 weeks or worsen with dose escalation, continuing the medication becomes untenable.

Solution: switch to semaglutide (lower GI side effect rate) or discontinue GLP-1 therapy and intensify insulin. Some patients tolerate tirzepatide better when titrated more slowly (4-week intervals instead of 2-week intervals between dose increases).

The decision to abandon combination therapy should be made collaboratively with a provider after at least 12 weeks of trial, unless severe adverse effects occur earlier.

Cost and insurance considerations

The financial calculus of combination therapy is complex.

Brand-name pricing (without insurance):

• Mounjaro: approximately $1,000 to $1,200 per month
• Insulin glargine (Lantus): approximately $300 to $400 per month (10 mL vial)
• Insulin degludec (Tresiba): approximately $500 to $600 per month
• Combination: $1,300 to $1,800 per month

With insurance:

• Coverage for Mounjaro varies widely; many plans require prior authorization and step therapy
• Insulin is typically covered with lower copays ($25 to $75 per month)
• Combination therapy may trigger higher out-of-pocket costs if both medications are in higher formulary tiers

Compounded tirzepatide option:

• Compounded tirzepatide: $200 to $400 per month depending on dose and pharmacy
• Combination with insulin: $250 to $500 per month total
• Not covered by insurance but often less expensive than brand-name copays

Long-term cost consideration:

• If the combination allows insulin discontinuation within 12 to 16 weeks, the temporary higher cost may be offset by long-term monotherapy savings
• Patients who remain on combination therapy long-term face sustained higher costs

Some insurance plans cover Mounjaro for diabetes (FDA-approved indication) but not for weight loss. If you have type 2 diabetes and are on insulin, the diabetes indication usually satisfies prior authorization requirements.

FormBlends offers compounded tirzepatide for patients who cannot access or afford brand-name Mounjaro. The combination of compounded tirzepatide + generic insulin is often the most cost-effective approach for uninsured or underinsured patients.

FAQ

Can you take insulin and Mounjaro at the same time? Yes. The combination is FDA-approved and clinically studied for type 2 diabetes. Both medications can be taken together safely with appropriate insulin dose reduction to prevent hypoglycemia. Most patients reduce insulin by 20% to 40% when starting Mounjaro.

Do you need to reduce insulin when starting Mounjaro? Yes, in most cases. If your A1C is below 8.5%, reduce basal insulin by 20% to 30% at Mounjaro initiation. If your A1C is below 7.5%, reduce by 30% to 40%. This prevents hypoglycemia as both medications lower blood sugar. Your provider will guide specific dose adjustments.

How long can you take insulin and Mounjaro together? There is no fixed time limit. Some patients use the combination for 8 to 12 weeks during Mounjaro titration, then discontinue insulin. Others remain on both long-term if needed for glucose control. About 60% of patients stop insulin within 16 weeks of starting Mounjaro.

Will Mounjaro replace my insulin? For many patients, yes. In the SURPASS-5 trial, patients reduced insulin doses by an average of 43% while on Mounjaro. Many patients discontinue insulin entirely. However, some patients with severe beta-cell dysfunction need both medications long-term.

Can you take Mounjaro with long-acting insulin like Lantus or Tresiba? Yes. Long-acting basal insulins (glargine, degludec, detemir) are the most common type combined with Mounjaro. The combination is well-studied and safe with dose adjustment. Reduce basal insulin by 20% to 30% when starting Mounjaro to prevent low blood sugar.

Can you take Mounjaro with fast-acting insulin like Humalog or Novolog? Yes, but bolus (mealtime) insulin often becomes unnecessary on Mounjaro. Reduce bolus insulin by 30% to 50% initially. Many patients eliminate mealtime insulin entirely within 8 to 12 weeks as Mounjaro controls post-meal glucose spikes through delayed gastric emptying.

What are the risks of taking insulin and Mounjaro together? The primary risk is hypoglycemia (low blood sugar below 70 mg/dL). Both medications lower glucose, creating additive effect. Other risks include nausea from Mounjaro and weight changes. The combination is safe when insulin doses are reduced appropriately and glucose is monitored regularly.

How do you know if you need both insulin and Mounjaro? If your A1C is above 8.5% on insulin alone, adding Mounjaro often produces better glucose control than increasing insulin. If your A1C is below 8%, you may be able to switch to Mounjaro alone. Your provider will assess based on glucose patterns, A1C, and treatment goals.

Can you take Mounjaro if you have type 1 diabetes and use insulin? Mounjaro is not FDA-approved for type 1 diabetes. It is approved only for type 2 diabetes and obesity. Some endocrinologists use GLP-1 medications off-label in type 1 diabetes, but this requires specialist supervision. Do not start Mounjaro for type 1 diabetes without provider guidance.

Does Mounjaro work better than insulin for type 2 diabetes? For most patients, yes. The SURPASS-3 trial showed tirzepatide produced 2.0% A1C reduction vs 1.1% for insulin degludec, plus 9.5 kg more weight loss. Mounjaro addresses multiple defects in type 2 diabetes (insulin resistance, incretin deficiency) while insulin addresses only insulin deficiency.

What should you do if your blood sugar goes too low on both medications? Treat immediately with 15 grams of fast-acting carbohydrate (4 glucose tablets, 4 oz juice, or 1 tablespoon honey). Recheck glucose in 15 minutes. If still below 70 mg/dL, repeat treatment. Contact your provider to reduce insulin dose. Frequent hypoglycemia means insulin dose is too high.

Can you take compounded tirzepatide with insulin? Yes. Compounded tirzepatide works through the same mechanism as brand-name Mounjaro. The combination with insulin requires the same dose adjustments and monitoring. Compounded tirzepatide is not FDA-approved but is commonly used with insulin in clinical practice through telehealth platforms like FormBlends.

Sources

1. Dahl D et al. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial. JAMA. 2022.
2. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
3. Del Prato S et al. Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial. JAMA. 2021.
4. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
5. Frias JP et al. Efficacy and safety of tirzepatide in patients with type 2 diabetes inadequately controlled with basal insulin: SURPASS-5 trial. Diabetes Care. 2022.
6. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
7. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
8. Blonde L et al. Interpretation and Impact of Real-World Clinical Data for the Practicing Clinician: Focus on Tirzepatide. Postgraduate Medicine. 2023.
9. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
10. Davies MJ et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
11. Heise T et al. Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinology. 2022.
12. Lingvay I et al. Efficacy and safety of once-weekly tirzepatide versus insulin degludec in participants with type 2 diabetes and increased cardiovascular risk: SURPASS-4 trial. Circulation. 2022.
13. Thomas MK et al. Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes. Journal of Clinical Endocrinology & Metabolism. 2021.
14. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro, Zepbound, Lantus, Tresiba, Humalog, and Novolog are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.